Suppr超能文献

抑制 TNF 通过 TRPV1 依赖性机制减少完全弗氏佐剂诱导的小鼠机械性口面部痛觉过敏。

Inhibition of TNF reduces mechanical orofacial hyperalgesia induced by Complete Freund's Adjuvant by a TRPV1-dependent mechanism in mice.

机构信息

Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warszawa, Poland.

Xencor, Inc., 111 West Lemon Avenue, Monrovia, CA, USA.

出版信息

Pharmacol Rep. 2017 Dec;69(6):1380-1385. doi: 10.1016/j.pharep.2017.05.013. Epub 2017 Jun 3.

Abstract

BACKGROUND

Inflammation in the orofacial region results in pain and is associated with many pathological states, including migraine, neuralgias and temporomandibular disorder. Although extensively studied, the mechanisms responsible for these conditions are not known and effective treatments are lacking. We reported earlier that the proinflammatory cytokine tumor necrosis factor (TNF) plays an important role in regulation of trigeminal ganglion (TG) neuron function in vitro. In the present study we investigated the role of TNF in mechanical hypersensitivity in mice.

METHODS

We employed the Complete Freund's Adjuvant (CFA)-induced model of orofacial pain and evaluated the effect of blocking of soluble TNF activity by peripheral administration of the novel dominant negative TNF biologic, XPro1595.

RESULTS

We show that CFA administration into the lower lip causes hyperalgesia and an increase in both expression of transient receptor potential vanilloid subfamily member 1 (TRPV1) mRNA and in the average intensity of TRPV1 protein immunoreactivity in TG neurons. We also show that intraperitoneal administration of XPro1595 prevents both CFA-induced mechanical hypersensitivity and, as shown in immunohistochemical staining - upregulation of TRPV1 protein expression in TG neurons.

CONCLUSIONS

We conclude that one of the possible regulatory mechanisms of TNF in pain involves upregulation of the nociceptor TRPV1, and that peripheral treatment with a selective anti-soluble TNF biologic can prevent hyperalgesia caused by inflammation in the orofacial region. Therefore, these new findings suggest that XPro1595 may serve as a novel treatment for orofacial pain disorders.

摘要

背景

口腔面部区域的炎症会导致疼痛,并与许多病理状态相关,包括偏头痛、神经痛和颞下颌关节紊乱。尽管已经进行了广泛的研究,但这些疾病的发病机制尚不清楚,也缺乏有效的治疗方法。我们之前报道过,促炎细胞因子肿瘤坏死因子(TNF)在体外调节三叉神经节(TG)神经元功能方面起着重要作用。在本研究中,我们研究了 TNF 在小鼠机械性痛敏中的作用。

方法

我们采用完全弗氏佐剂(CFA)诱导的口腔疼痛模型,并通过外周给予新型显性负性 TNF 生物制剂 XPro1595 来评估阻断可溶性 TNF 活性的作用。

结果

我们发现,CFA 注射到下唇会引起痛觉过敏,并导致 TG 神经元中瞬时受体电位香草酸亚型 1(TRPV1)mRNA 的表达增加和 TRPV1 蛋白免疫反应性的平均强度增加。我们还发现,XPro1595 的腹腔内给药可预防 CFA 诱导的机械性痛敏,以及免疫组织化学染色显示的 TG 神经元中 TRPV1 蛋白表达的上调。

结论

我们得出结论,TNF 在疼痛中的一种可能调节机制涉及伤害感受器 TRPV1 的上调,而外周给予选择性抗可溶性 TNF 生物制剂可预防口腔面部区域炎症引起的痛觉过敏。因此,这些新发现表明,XPro1595 可能成为口腔疼痛障碍的一种新的治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验